These novel findings provide another important evidence to support a broad range of pharmacological designs targeting EPHB4 or the Eph/Ephrin interaction to prevent or cure some types of cancer.30–32 These findings may also be significant in ESCC early detection by using the EPHB4-specific examination established in the future. Here, EPHB4 is linked to esophageal squamous cell carcinoma.